TheraRadar
← Back
Data updated: Jun 28, 2026

MANNKIND

Biotech
MetabolicRespiratoryInfectious Disease Execution: Fair

MANNKIND is a biotechnology company focused on Metabolic, Respiratory, Infectious Disease. Key products include AFREZZA.

2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics

MANNKIND at a Glance

  • Growing R&D activity with 4 trials in last 2 years
  • Fast trial execution (10 months median completion)

MANNKIND's Key Drugs

MANNKIND's core commercial portfolio centers on AFREZZA, spanning Metabolic and Respiratory — its most strategically important drugs approved in the last 15 years.

AFREZZA
Metabolic

Diabetes

Approved 2014

MANNKIND's Recent FDA Approvals

New NDA/BLA approvals for MANNKIND over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MANNKIND's Therapeutic Areas

MANNKIND's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Respiratory, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 76%
1 drugs Phase 3: 6 Phase 2: 4 Phase 1: 9
Respiratory 11%
0 drugs Phase 3: 1 Phase 1: 3
Infectious Disease 6%
0 drugs Phase 3: 1
Oncology 5%
0 drugs Phase 2: 1 Phase 1: 1
Cardiovascular 2%
0 drugs Phase 1: 1

MANNKIND Pipeline Snapshot

MANNKIND has 27 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 5 Phase 2 and 14 Phase 1.

8
Phase 3
5
Phase 2
14
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • AFREZZA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Metabolic pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/7 completed
  • • Speed: 10 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges